Compare H2O America (HTO) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
H2O America vs State Street SPDR S&P Biotech ETF — how do they compare? H2O America trades at $58.48 (market cap $2.43B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 4.2× H2O America's market cap, and H2O America pays a 3.03% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold H2O America for 40 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| HTO | XBI | |
|---|---|---|
Market Cap | $2.43B | $10.11B |
Volume | 593,883 | 12,903,266 |
Sector | Utilities | Broad Market / Factor |
52-Week High | $65.43 | $169.55 |
52-Week Low | $44.44 | $104.99 |
Typical Hold Time | 40 Days | 38 Days |
Enterprise Value | $4.22B | — |
Dividend Yield | 3.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HTO trades at $58.48, up 0.86% with a bearish technical signal despite bullish oscillators. The company shows stable fundamentals with 12.91% net margin and consistent earnings beats in recent quarters. Recent Texas acquisitions signal growth strategy, though cash flow trends show heavy investment activity. Analyst consensus remains strongly bullish with 83% buy ratings and $66.50 price target.
HTO presents a compelling value opportunity with strong analyst support and strategic expansion, though execution risks from recent acquisitions and bearish technical indicators warrant caution. The stock's current discount to consensus target offers potential upside for patient investors willing to navigate near-term volatility.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
